KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Investing Activities (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Cash from Investing Activities for 17 consecutive years, with -$42.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 155.56% year-over-year to -$42.4 million, compared with a TTM value of -$414.2 million through Dec 2025, down 403.49%, and an annual FY2025 reading of -$414.2 million, down 403.49% over the prior year.
  • Cash from Investing Activities was -$42.4 million for Q4 2025 at Biomarin Pharmaceutical, up from -$331.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $90.5 million in Q2 2024 and bottomed at -$331.0 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$38.8 million, with a median of -$29.9 million recorded in 2022.
  • The sharpest move saw Cash from Investing Activities soared 224.01% in 2022, then crashed 1948.42% in 2025.
  • Year by year, Cash from Investing Activities stood at -$55.4 million in 2021, then grew by 1.28% to -$54.7 million in 2022, then fell by 18.74% to -$65.0 million in 2023, then skyrocketed by 217.61% to $76.4 million in 2024, then tumbled by 155.56% to -$42.4 million in 2025.
  • Business Quant data shows Cash from Investing Activities for BMRN at -$42.4 million in Q4 2025, -$331.0 million in Q3 2025, and -$12.6 million in Q2 2025.